Nutritional Epigenetics and the Prevention of Hepatocellular Carcinoma with Bioactive Food Constituents

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, et al.: Global cancer statistics, 2012. CA Cancer J Clin 65, 87–108, 2015.
   PubMed Web of Science ®Google Scholar
• El-Serag HB: Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142, 1264–1273, 2012.
   PubMed Web of Science ®Google Scholar
• Stewart BW and Wild CP: World Cancer Report 2014. International Agency for Research on Cancer, Lyon, France, 2014.
   Google Scholar
• El-Serag HB and Kanwal F: Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology 60, 767–1775, 2014.
   Web of Science ®Google Scholar
• Stickel F: Alcoholic cirrhosis and hepatocellular carcinoma. Adv Exp Med Biol 815, 113–130, 2015.
   PubMed Web of Science ®Google Scholar
• Simard EP, Ward EM, Siegel R, and Jemal A: Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 62, 118–128, 2012.
   PubMed Web of Science ®Google Scholar
• American Association for Cancer Research: AACR Cancer Progress Report 2014. Clin Cancer Res 20, S1–S112, 2014.
   PubMed Web of Science ®Google Scholar
• Altekruse SF, McGlynn KA, and Reichman ME: Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 27, 1485–1491, 2009.
   PubMed Web of Science ®Google Scholar
• Singal AG and El-Serag HB: Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice. Clin Gastroenterol Hepatol 13, 2140–2151, 2015.
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, et al.: Cancer genome landscapes. Science 339, 1546–1558, 2013.
   PubMed Web of Science ®Google Scholar
• Villanueva A and Llovet JM: Mutational landscape of HCC—the end of beginning. Nat Rev Clin Oncol 11, 73–74, 2014.
   PubMed Web of Science ®Google Scholar
• Hussain SP, Schwank J, Staib F, Wang XW, and Harris CC: TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 26, 2166–2176, 2007.
   PubMed Web of Science ®Google Scholar
• Tornesello ML, Buonaguro L, Tatangelo F, Botti G, Izzo F, et al.: Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections. Genomics 102, 74–83, 2013.
   PubMed Web of Science ®Google Scholar
• Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, et al.: High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun 4, 2218, 2013.
   PubMed Web of Science ®Google Scholar
• Zucman-Rossi J, Villanueva A, Nault JC, and Llovet JM: The genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology 149, 1226–1239, 2015.
   PubMed Web of Science ®Google Scholar
• Nault JC, Calderaro J, Di Tommaso L, Balabaudet C, Zafrani ES, et al.: Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology 60, 1983–1992, 2014.
   PubMed Web of Science ®Google Scholar
• Nishida N and Goel A: Genetic and epigenetic signatures in human hepatocellular carcinoma: a systematic review. Curr Genomics 12, 130–137, 2011.
   PubMed Web of Science ®Google Scholar
• Pogribny IP and Rusyn I: Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma. Cancer Lett 342, 223–230, 2014.
   PubMed Web of Science ®Google Scholar
• Wang ZC, Gao Q, Shi JY, Guo WJ, Yang LX, et al.: PTPRS acts as a metastatic suppressor in hepatocellular carcinoma by control of EGFR induced epithelial-mesenchymal transition. Hepatology, 62, 1201–1214, 2015.
   PubMed Web of Science ®Google Scholar
• Xie Q, Chen L, Shan X, Shan X, Tang J, et al.: Epigenetic silencing of SFRP1 and SFRP5 by hepatitis B virus X protein enhances hepatoma cell tumorigenicity through Wnt signaling pathway. Int J Cancer 135, 635–646, 2014.
   PubMed Web of Science ®Google Scholar
• Anwar SL, Krech T, Hasemeier B, Schipper E, Schweitzer N, et al.: Deregulation of RB1 expression by loss of imprinting in human hepatocellular carcinoma. J Pathol 233, 392–401, 2014.
   PubMed Web of Science ®Google Scholar
• Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, et al.: Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 117, 2713–2722, 2007.
   PubMed Web of Science ®Google Scholar
• Martin M and Herceg Z: From hepatitis to hepatocellular carcinoma: a proposed model for crosstalk between inflammation and epigenetic mechanisms. Genome Med 4, 8, 2012.
   Google Scholar
• Fernández-Alvarez A, Llorente-Izquierdo C, Mayoral R, Agra N, Bosca L, et al.: Evaluation of epigenetic modulation of cyclooxygenase-2 as a prognostic marker for hepatocellular carcinoma. Oncogenesis 1, e23, 2012.
   PubMed Web of Science ®Google Scholar
• Nishida N and Kudo M: Oxidative stress and epigenetic instability in human hepatocarcinogenesis. Dig Dis 31, 447–453, 2013.
   PubMed Web of Science ®Google Scholar
• Lim SO, Gu JM, Kim MS, Kim HS, Park YN, et al.: Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter. Gastroenterology 135, 2128–2140, 2008.
   PubMed Web of Science ®Google Scholar
• Xue X, Gao W, Sun B, Xu Y, Han B, et al.: Vasohibin 2 is transcriptionally activated and promotes angiogenesis in hepatocellular carcinoma. Oncogene 32, 1724–1734, 2013.
   PubMed Web of Science ®Google Scholar
• Forner A, Gilabert M, Bruix J, and Raoul JL: Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol 11, 525–535, 2014.
   PubMed Web of Science ®Google Scholar
• Singh S, Singh PP, Roberts LR, and Sanchez W: Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 11, 45–54, 2014.
   PubMed Web of Science ®Google Scholar
• Ooi SK, O'Donnell AH, and Bestor TH: Mammalian cytosine methylation at a glance. J Cell Sci 122, 2787–2791, 2009.
   PubMed Web of Science ®Google Scholar
• Chen ZX and Riggs AD: DNA methylation and demethylation in mammals. J Biol Chem 286, 18347–18353, 2011.
   PubMed Web of Science ®Google Scholar
• Wu H and Zhang Y: Reversing DNA methylation: mechanisms, genomics, and biological functions. Cell 156, 45–68, 2014.
   PubMed Web of Science ®Google Scholar
• Kohli RM and Zhang Y: TET enzymes, TDG and the dynamics of DNA demethylation. Nature 502, 472–479, 2013.
   PubMed Web of Science ®Google Scholar
• Hamm S, Just G, Lacoste N, Moitessier N, Szyf M, et al.: On the mechanism of demethylation of 5-methylcytosine in DNA. Bioorg Med Chem Lett 18, 1046–1049, 2008.
   PubMed Web of Science ®Google Scholar
• Zhu B, Zheng Y, Angliker H, Schwarz S, Thiry S, et al.: 5-Methylcytosine DNA glycosylase activity is also present in the human MBD4 (G/T mismatch glycosylase) and in a related avian sequence. Nucleic Acids Res 28, 4157–4165, 2000.
   PubMed Web of Science ®Google Scholar
• Kienhöfer S, Musheev MU, Stapf U, Helm M, Schomacher L, et al.: GADD45a physically and functionally interacts with TET1. Differentiation 90, 59–68, 2015.
   PubMed Web of Science ®Google Scholar
• Li Z, Gu T-P, Weber AR, Shen J-Z, Li B-Z, et al.: Gadd45a promotes DNA demethylation through TDG. Nucleic Acids Res 43, 3986–3997, 2015.
   PubMed Web of Science ®Google Scholar
• Lin CH, Hsieh SY, Sheen IS, Lee WC, Chen TC, et al.: Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer Res 61, 4238–4243, 2001.
   PubMed Web of Science ®Google Scholar
• Tischoff I and Tannapfe A: DNA methylation in hepatocellular carcinoma. World J Gastroenterol 14, 1741–1748, 2008.
   PubMed Web of Science ®Google Scholar
• Stefanska B, Huang J, Bhattacharyya B, Suderman M, Hallett M, et al.: Definition of the landscape of promoter DNA hypomethylation in liver cancer. Cancer Res 71, 5891–5903, 2011.
   PubMed Web of Science ®Google Scholar
• Udali S, Guarini P, Moruzzi S, Ruzzenente A, Tammen SA, et al.: Global DNA methylation and hydroxymethylation differ in hepatocellular carcinoma and cholangiocarcinoma and relate to survival rate. Hepatology 62, 496–504, 2015.
   PubMed Web of Science ®Google Scholar
• Nishida N, Kudo M, Nishimura T, Arizumi T, Takita M, et al.: Unique association between global DNA hypomethylation and chromosomal alterations in human hepatocellular carcinoma. PLoS One 8, e72312, 2013.
   PubMed Web of Science ®Google Scholar
• Stefanska B, Cheishvili D, Suderman M, Arakelian A, Huang J, et al.: Genome-wide study of hypomethyalted and induced genes in patients with liver cancer unravels novel anticancer targets. Clin Cancer Res 20, 3118–3132, 2014.
   PubMed Web of Science ®Google Scholar
• Fan H, Zhang H, Pascuzzi PE, and Andrisani O: Hepetitis B virus X protein induces EpCAM expression via active DNA demethylation directed by RelA in complex with EZH2 and TET2. Oncogene 35, 715–726, 2016.
   PubMed Web of Science ®Google Scholar
• Saito Y, Kanai Y, Sakamoto M, Saito H, Ishii H, et al.: Expression of mRNA for DNA methyltransferases and methyl-CpG-binding proteins and DNA methylation status on CpG islands and pericentromeric satellite regions during human hepatocarcinogenesis. Hepatology 33, 561–568, 2001.
   PubMed Web of Science ®Google Scholar
• Saito Y, Kanai Y, Nakagawa T, Sakamoto M, Saito H, et al.: Increased protein expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the malignant potential and poor prognosis of human hepatocellular carcinomas. Int J Cancer 105, 27–532, 2003.
   Web of Science ®Google Scholar
• Fan H, Zhao ZJ, Cheng J, Su XW, Wu QX, et al.: Overexpression of DNA methyltransferase 1 and its biological significance in primary hepatocellular carcinoma. World J Gastroenterol 15, 2020–2026, 2009.
   PubMed Web of Science ®Google Scholar
• Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A, et al.: UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma. Cancer Cell 25, 196–209, 2014.
   PubMed Web of Science ®Google Scholar
• Stefanska B, Suderman M, Machnes Z, Bhattacharyya B, Hallett M, et al.: Transcription onset of genes critical in liver carcinogenesis is epigenetically regulated by methylated DNA-binding protein MBD2. Carcinogenesis 34, 2738–2749, 2013.
   PubMed Web of Science ®Google Scholar
• Saito Y, Kanai Y, Sakamoto M, Saito H, Ishii H, et al.: Overexpression of a splice variant of DNA methyltransferase 3b, DNMT3b4, associated with DNA hypomethylation on pericentromeric satellite regions during human hepatocarcinogenesis. Proc Natl Acad Sci USA 99, 10060–10065, 2002.
   PubMed Web of Science ®Google Scholar
• Kouzarides T: Chromatin modifications and their function. Cell 128, 693–705, 2007.
   PubMed Web of Science ®Google Scholar
• Bannister AJ and Kouzarides T: Regulation of chromatin by histone modifications. Cell Res 21, 381–395, 2011.
   PubMed Web of Science ®Google Scholar
• Pogribny IP, Ross SA, Tryndyak VP, Pogribna M, Poirier LA, et al.: Histone H3 lysine 9 and H4 lysine 20 trimethylation and the expression of Suv4-20h2 and Suv-39h1 histone methyltransferases in hepatocarcinogenesis induced by methyl deficiency in rats. Carcinogenesis 27, 1180–1186, 2006.
   PubMed Web of Science ®Google Scholar
• Sistayanarain A, Tsuneyama K, Zheng H, Takahashi H, Nomoto K, et al.: Expression of Aurora-B kinase and phosphorylated histone H3 in hepatocellular carcinoma. Anticancer Res 26, 3585–3593, 2006.
   PubMed Web of Science ®Google Scholar
• Cai MY, Hou JH, Rao HL, Luo RZ, Li M, et al.: High expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts worse prognosis in patients. Mol Med 17, 12–20, 2011.
   PubMed Web of Science ®Google Scholar
• Hayashi A, Yamauchi N, Shibahara J, Kimura H, Morikawa T, et al.: Concurrent activation of acetylation and tri-methylation of H3K27 in a subset of hepatocellular carcinoma with aggressive behavior. PLoS One 9, e91330, 2014.
   PubMed Web of Science ®Google Scholar
• He C, Xu J, Zhang J, Xie D, Ye H, et al.: High expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma. Hum Pathol 43, 1425–1435, 2012.
   PubMed Web of Science ®Google Scholar
• Sudo T, Utsunomiya T, Mimori K, Nagahara H, Ogawa K, et al.: Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer 92, 1754–1758, 2005.
   PubMed Web of Science ®Google Scholar
• Fan DN, Tsang FH, Tam AH, Au SL, Wong CC, et al.: Histone lysine methyltransferase, suppressor of variegation 3-9 homolog 1, promotes hepatocellular carcinoma progression and is negatively regulated by microRNA-125b. Hepatology 57, 637–647, 2013.
   PubMed Web of Science ®Google Scholar
• Chiba T, Saito T, Yuki K, Zen Y, Koide S, et al.: Histone lysine methyltransferase SUV39H1 is a potent target for epigenetic therapy of hepatocellular carcinoma. Int J Cancer 136, 289–298, 2015.
   PubMed Web of Science ®Google Scholar
• Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva FP, et al.: SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol 6, 731–740, 2004.
   PubMed Web of Science ®Google Scholar
• Au SL, Wong CC, Lee JM, Wong CM, and Ng IO: EZH2-Mediated H3K27me3 is involved in epigenetic repression of deleted in liver cancer 1 in human cancers. PLoS One 8, e68226, 2013.
   PubMed Web of Science ®Google Scholar
• Au SL, Wong CC, Lee JM, Fan DN, Tsang FH, et al.: Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. Hepatology 56, 622–631, 2012.
   PubMed Web of Science ®Google Scholar
• Cheng AS, Lau SS, Chen Y, Kondo Y, Li MS, et al.: EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis. Cancer Res 71, 4028–4039, 2011.
   PubMed Web of Science ®Google Scholar
• Viré E, Brenner C, Deplus R, Blanchon L, Fraga M, et al.: The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439, 871–874, 2006.
   PubMed Web of Science ®Google Scholar
• Zhao ZK, Yu HF, Wang DR, Dong P, Chen L, et al.: Overexpression of lysine specific demethylase 1 predicts worse prognosis in primary hepatocellular carcinoma patients. World J Gastroenterol 18, 6651–6656, 2012.
   PubMed Web of Science ®Google Scholar
• Liang X, Zeng J, Wang L, Fang M, Wang Q, et al.: Histone demethylase retinoblastoma binding protein 2 is overexpressed in hepatocellular carcinoma and negatively regulated by hsa-miR-212. PLos One 8, e69784, 2013.
   PubMed Web of Science ®Google Scholar
• Cech TR and Steitz JA: The noncoding RNA revolution-trashing old rules to forge new ones. Cell 157, 77–94, 2014.
   PubMed Web of Science ®Google Scholar
• St Laurent G, Wahlestedt C, and Kapranov P: The landscape of long noncoding RNA classification. Trends Genet 31, 239–251, 2015.
   PubMed Web of Science ®Google Scholar
• Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, et al.: The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res 22, 1775–1789, 2012.
   PubMed Web of Science ®Google Scholar
• Londin E, Loher P, Telonis AG, Quann K, Clark P, et al.: Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. Proc Natl Acad USA 112, E1106–E1115, 2015.
   PubMed Web of Science ®Google Scholar
• Quagliata L, Matter MS, Piscuoglio S, Arabi L, Ruiz C, et al.: Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. Hepatology 59, 911–923, 2014.
   PubMed Web of Science ®Google Scholar
• Huang JL, Zheng L, Hu YW, and Wang Q: Characteristics of long non-coding RNA and its relation to hepatocellular carcinoma. Carcinogenesis 35, 507–514, 2014.
   PubMed Web of Science ®Google Scholar
• Li C, Chen J, Zhang K, Feng B, Wang R, et al.: Progress and prospects of long noncoding RNAs (lncRNAs) in hepatocellular carcinoma. Cell Physiol Biochem 36, 423–434, 2015.
   PubMed Web of Science ®Google Scholar
• Cui M, Xiao Z, Wang Y, Zheng M, Song T, et al.: Long noncoding RNA HULC modulates abnormal lipid metabolism in hepatoma cells through an miR-9-mediated RXPA signaling pathway. Cancer Res 75, 846–857, 2015.
   PubMed Web of Science ®Google Scholar
• Yuan SX, Wang J, Yang F, Tao QF, Zhang J, et al.: Long noncoding RNA DANCR increases stemness features of hepatocellular carcinoma via de-repression of CTNNB1. Hepatology 63, 499–511, 2016.
   PubMed Web of Science ®Google Scholar
• Fu WM, Zhu X, Wang WM, Lu YF, Hu BG, et al.: Hotair mediates hepatocarcinogenesis through suppressing MiRNA-218 expression and activating P14 and P16 signaling. J Hepatol 63, 886–895, 2015.
   PubMed Web of Science ®Google Scholar
• Li T, Xie J, Shen C, Cheng D, Shi Y, et al.: Upregulation of long noncoding RNA ZEB1-AS1 promotes tumor metastasis and predicts poor prognosis in hepatocellular carcinoma. Oncogene 35, 1575–1584, 2016.
   PubMed Web of Science ®Google Scholar
• Negrini M, Gramantieri L, Sabbioni S, and Croce CM: microRNA involvement in hepatocellular carcinoma. Anticancer Agents Med Chem 11, 500–521, 2011.
   PubMed Web of Science ®Google Scholar
• Braconi C, Henry JC, Kogure T, Schmittgen T, and Patel T: The role of microRNAs in human liver cancers. Semin Oncol 38, 752–763, 2011.
   PubMed Web of Science ®Google Scholar
• Szabo G and Bala S: MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol 10, 542–552, 2013.
   PubMed Web of Science ®Google Scholar
• Otsuka M, Kishikawa T, Yoshikawa T, Ohno M, Takata A, et al.: The role of microRNAs in hepatocarcinogenesis: current knowledge and future prospects. J Gastroenterol 49, 173–184, 2014.
   PubMed Web of Science ®Google Scholar
• Bandiera S, Pfeffer S, Baumert TF, and Zeisel MB: miR-122—a key factor and therapeutic target in liver disease. J Hepatol 62, 448–457, 2015.
   PubMed Web of Science ®Google Scholar
• Kutay H, Bai S, Datta J, Motiwala T, Pogribny I, et al.: Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 99, 671–678, 2006.
   PubMed Web of Science ®Google Scholar
• Coulouarn C, Factor VM, Andersen JB, Durkin ME, and Thorgeirsson SS: Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 28, 3526–3536, 2009.
   PubMed Web of Science ®Google Scholar
• Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, et al.: MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 122, 2884–2897, 2012.
   PubMed Web of Science ®Google Scholar
• Tili E, Croce CM, and Michaille JJ: miR-155: on the crosstalk between inflammation and cancer. Int Rev Immunol 28, 264–284, 2009.
   PubMed Web of Science ®Google Scholar
• Vigorito E, Kohlhaas S, Lu D, and Leyland R: miR-155: an ancient regulator of the immune system. Immunol Rev 253, 146–157, 2013.
   PubMed Web of Science ®Google Scholar
• Wang B, Majumder S, Nuovo G, Kutay H, Volinia S, et al.: Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology 50, 1152–1161, 2009.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wei W, Cheng N, Wang K, Li B, et al.: Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling. Hepatology 56, 1631–1640, 2012.
   PubMed Web of Science ®Google Scholar
• Yan XL, Jia YL, Chen L, Zeng Q, Zhou JN, et al.: Hepatocellular carcinoma-associated mesenchymal stem cells promote hepatocarcinoma progression: role of the S100A4-miR155-SOCS1-MMP9 axis. Hepatology 57, 2274–2286, 2013.
   PubMed Web of Science ®Google Scholar
• Ji J, Zheng X, Forgues M, Yamashita T, Wauthier EL, et al.: Identification of MicroRNAs specific for EpCAM+ tumor cells in hepatocellular carcinoma. Hepatology 62, 829–840, 2015.
   PubMed Web of Science ®Google Scholar
• Hazra A, Kraft P, Lazarus R, Chen C, Chanock SJ, et al.: Genome-wide significant predictors of metabolites in the one-carbon metabolism pathway. Hum Mol Genet 18, 4677–4687, 2009.
   PubMed Web of Science ®Google Scholar
• Stover PJ: Polymorphisms in 1-carbon metabolism, epigenetics and folate-related pathologies. J Nutrigenet Nutrigenomics 4, 293–305, 2011.
   PubMed Web of Science ®Google Scholar
• Finkelstein JD: Metabolic regulatory properties of S-adenosylmethionine and S-adenosylhomocysteine. Clin Chem Lab Med 45, 1694–1699, 2007.
   PubMed Web of Science ®Google Scholar
• Liang CR, Leow CK, Neo JC, Tan GS, Lo SL, et al.: Proteome analysis of human hepatocellular carcinoma tissues by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics 5, 2258–2271, 2005.
   PubMed Web of Science ®Google Scholar
• Huang Q, Tan Y, Yin P, Ye G, Gao P, et al.: Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics. Cancer Res 73, 4992–5002, 2013.
   PubMed Web of Science ®Google Scholar
• Frau M, Feo F, and Pascale RM: Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis. J Hepatol 59, 830–841, 2013.
   PubMed Web of Science ®Google Scholar
• Teng YW, Mehedint MG, Garrow TA, and Zeisel SH: Deletion of betaine-homocysteine S-methyltransferase in mice perturbs choline and 1-carbon metabolism, resulting in fatty liver and hepatocellular carcinomas. J Biol Chem 286, 36258–36267, 2011.
   PubMed Web of Science ®Google Scholar
• Martínez-Chantar ML, Vázquez-Chantada M, Ariz U, Martínez N, Varela M, et al.: Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice. Hepatology 47, 1191–1199, 2008.
   PubMed Web of Science ®Google Scholar
• Poirier LA: Methyl group deficiency in hepatocarcinogenesis. Drug Metab Rev 26, 185–199, 1994.
   PubMed Web of Science ®Google Scholar
• Nakae D: Endogenous liver carcinogenesis in the rat. Pathol Int 49, 1028–1042, 1999.
   PubMed Web of Science ®Google Scholar
• Pogribny IP, James SJ, and Beland FA: Molecular alterations in hepatocarcinogenesis induced by dietary methyl deficiency. Mol Nutr Food Res 56, 116–125, 2012.
   PubMed Web of Science ®Google Scholar
• Corbin KD and Zeisel SH: Choline metabolism provides novel insights into nonalcoholic fatty liver disease and progression. Curr Opin Gastroenterol 28, 159–165, 2012.
   PubMed Web of Science ®Google Scholar
• Corbin KD, Abdelmalek MF, Spencer MD, da Costa KA, Galanko JA, et al.: Genetic signatures in choline and 1-carbon metabolism are associated woth the severity of hepatic steatosis. FASEB J 27, 1674–1689, 2013.
   PubMed Web of Science ®Google Scholar
• Qi X, Sun X, Xu J, Wang Z, Zhang J, et al.: Associations between methylenetetrahydrofolate reductase polymorphisms and hepatocellular carcinoma risk in Chinese population. Tumour Biol 35, 1757–1762, 2014.
   PubMed Web of Science ®Google Scholar
• Zhang H, Liu C, Han YC, Ma Z, Zhang H, et al.: Genetic variations in the one-carbon metabolism pathway genes and susceptibility to hepatocellular carcinoma risk: a case-control study. Tumour Biol 36, 997–1002, 2015.
   PubMed Web of Science ®Google Scholar
• Kuo CS, Lin Cy, Wu MY, Lu CL, and Huang RF: Relationship between folate status and tumour progression in patients with hepatocellular carcinoma. Br J Nutr 100, 596–602, 2008.
   PubMed Web of Science ®Google Scholar
• de Carvalho SC, Muniz MT, Siqueira MD, Siqueira ER, Gomes AV, et al.: Plasmatic higher levels of homocysteine in non-alcoholic fatty liver disease (NAFLD). Nutr J 12, 37, 2013.
   PubMed Web of Science ®Google Scholar
• Brunaud L, Alberto JM, Ayav A, Gerard P, Namour F, et al.: Effects of vitamin B12 and folate deficiencies on DNA methylation and carcinogenesis in rat liver. Clin Chem Lab Med 41, 1012–1019, 2003.
   PubMed Web of Science ®Google Scholar
• Pogribny IP, Shpyleva SI, Muskhelishvili L, Bagnyukova TV, James SJ, et al.: Role of DNA damage and alterations in cytosine DNA methylation in rat liver carcinogenesis induced by a methyl-deficient diet. Mutat Res 669, 56–62, 2009.
   PubMed Web of Science ®Google Scholar
• Huidobro C, Toraño EG, Fernández AF, Urdinguio RG, Rodriguez RM, et al.: A DNA methylation signature associated with the epigenetic repression of glycine N-methyltransferase in human hepatocellular carcinoma. J Mol Med (Berl) 91, 939–950, 2013.
   PubMed Web of Science ®Google Scholar
• Mirbahai L, Southam AD, Sommer U, Williams TD, Bignell JP, et al.: Disruption of DNA methylation via S-adenosylhomocysteine is a key process in high incidence liver carcinogenesis in fish. J Proteome Res 12, 2895–2904, 2013.
   PubMed Web of Science ®Google Scholar
• Fullerton FR, Hoover K, Mikol YB, Creasia DA, and Poirier LA: The inhibition by methionine and choline of liver carcinoma formation in male C3H mice dosed with diethynitrosamine and fed phenobarbital. Carcinogenesis 11, 1301–1305, 1990.
   PubMed Web of Science ®Google Scholar
• Pascale RM, Marras V, Daino L, Pinna G, et al.: Chemoprevention of rat liver carcinogenesis by S-adenosyl-L-methionine: a long-term study. Cancer Res 52, 4979–4986, 1992.
   PubMed Web of Science ®Google Scholar
• Pascale RM, Simile MM, De Miglio MR, Nufris A, Daino L, et al.: Chemoprevention by S-adenosyl-L-methionine of rat liver carcinogenesis initiated by 1,2-dimethylhydrazine and promoted by orotic acid. Carcinogenesis 16, 427–430, 1995.
   PubMed Web of Science ®Google Scholar
• Simile MM, Saviozzi M, De Miglio MR, Muroni MR, Nufris A, et al.: Persistent chemopreventive effect of S-adenosyl-L-methionine on the development of liver putative preneoplastic lesions induced by thiobenzamide in diethylnitrosamine-initiated rats. Carcinogenesis 17, 1533–1537, 1996.
   PubMed Web of Science ®Google Scholar
• Pascale RM, Simile MM, De Miglio MR, and Feo F: Chemoprevention of hepatocarcinogenesis: S-adenosyl-L-methionine. Alcohol 27, 193–198, 2002.
   PubMed Web of Science ®Google Scholar
• Pogribny IP, Ross SA, Wise C, Pogribna M, Jones EA, et al.: Irreversible global DNA hypomethylation as a key step in hepatocarcinogenesis induced by dietary methyl deficiency. Mutat Res 593, 80–87, 2006.
   PubMed Web of Science ®Google Scholar
• Chagas CE, Bassoli BK, de Souza CA, Deminice R, Jordao Junior AA, et al.: Folic acid supplementation during early hepatocarcinogenesis: cellular and molecular effects. Int J Cancer 129, 2073–2082, 2011.
   PubMed Web of Science ®Google Scholar
• Cordero P, Campion J, Milagro FI, and Martinez JA: Dietary supplementation with methyl donor groups could prevent nonalcoholic fatty liver. Hepatology 53, 2151–2152, 2011.
   PubMed Web of Science ®Google Scholar
• Kawakami S, Han KH, Nakamura Y, Shimada K, Kitano T, et al.: Effects of dietary supplementation with betaine on a nonalcoholic steatohepatitis (NASH) mouse model. J Nutr Sci Vitaminol (Tokyo) 58, 371–375, 2012.
   PubMed Web of Science ®Google Scholar
• Al Rajabi A, Castro GS, da Silva RP, Nelson RC, Thiesen A, et al.: Choline supplementation protects against liver damage by normalizing cholesterol metabolism in Pemt/Ldlr knockout mice fed a high-fat diet. J Nutr 144, 252–257, 2014.
   PubMed Web of Science ®Google Scholar
• Cordero P, Gomez-Uriz AM, Campion J, Milagro FI, and Martinez JA: Dietary supplementation with methyl donors reduces fatty liver and modifies the fatty acid synthase DNA methylation profile in rats fed an obesogenic diet. Genes Nutr 8, 105–113, 2013.
   PubMed Web of Science ®Google Scholar
• Wang LJ, Zhang HW, Zhou JY, Liu Y, Yang Y, et al.: Betaine attenuates hepatic steatosis by reducing methylation of the MTTP promoter and elevating genomic methylation in mice fed a high-fat diet. J Nutr Biochem 25, 329–336, 2014.
   PubMed Web of Science ®Google Scholar
• Tan AC, Konczak I, Sze DM, and Ramzan I: Molecular pathways for cancer chemoprevention by dietary phytochemicals. Nutr Cancer 63, 495–505, 2011.
   PubMed Web of Science ®Google Scholar
• Darvesh AS and Bishayee A: Chemopreventive and therapeutic potential of tea polyphenols in hepatocellular cancer. Nutr Cancer 65, 329–344, 2013.
   PubMed Web of Science ®Google Scholar
• Gerhauser C: Cancer chemoprevention and nutriepigenetics: state of the art and future challenges. Top Curr Chem 329, 73–132, 2013.
   PubMed Web of Science ®Google Scholar
• Matsumoto N, Kohri T, Okushio K, and Hara Y: Inhibitory effects of tea catechins, black tea extract and oolong tea extract on hepatocarcinogenesis in rat. Jpn J Cancer Res 87, 1034–1038, 1996.
   PubMedGoogle Scholar
• Sumi T, Shirakami Y, Shimizu M, Kochi T, Ohno T, et al.: (−)-Epigallocatechin-3-gallate suppresses hepatic preneoplastic lesions developed in a novel rat model of non-alcoholic steatohepatitis. Springerplus 2, 690, 2013.
   PubMed Web of Science ®Google Scholar
• Kochi T, Shimizu M, Terakura D, Baba A, Ohno T, et al.: Non-alcoholic steatohepatitis and preneoplastic lesions develop in the liver of obese and hypertensive rats: suppressing effects of EGCG on the development of liver lesions. Cancer Lett 342, 60–69, 2014.
   PubMed Web of Science ®Google Scholar
• Ding Y, Sun X, Chen Y, Deng Y, and Qian K: Epigallocatechin gallate attenuated non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet. Eur J Pharmacol 761, 405–412, 2015.
   PubMed Web of Science ®Google Scholar
• Calland N, Albecka A, Belouzard S, Wychowski C, Duverlie G, et al.: (−)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry. Hepatology 55, 720–729, 2012.
   PubMed Web of Science ®Google Scholar
• Chen C, Qiu H, Gong J, Liu Q, Xiao H, et al.: (−)-Epigallocatechin-3-gallate inhibits the replication cycle of hepatitis C virus. Arch Virol 157, 1301–1312, 2012.
   PubMed Web of Science ®Google Scholar
• Huang HC, Tao MH, Hung TM, Chen JC, Lin ZJ, et al.: (−)-Epigallocatechin-3-gallate inhibits entry of hepatitis B virus into hepatocytes. Antiviral Res 111, 100–111, 2014.
   PubMed Web of Science ®Google Scholar
• Singh BN, Shankar S, and Srivastava RK: Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol 82, 1807–1821, 2011.
   PubMed Web of Science ®Google Scholar
• Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, et al.: Tea polyphenol (−)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 63, 7563–7570, 2003.
   PubMed Web of Science ®Google Scholar
• Lee WJ, Shim JY, and Zhu BT: Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Mol Pharmacol 68, 1018–1030, 2005.
   PubMed Web of Science ®Google Scholar
• Achour M, Mousli M, Alhosin M, Ibrahim A, Peluso J, et al.: Epigallocatechin-3-gallate up-regulates tumor suppressor gene expression via a reactive oxygen species-dependent down-regulation of UHRF1. Biochem Biophys Res Commun 430, 208–212, 2013.
   PubMed Web of Science ®Google Scholar
• Moseley VR, Morris J, Knackstedt RW, and Wargovich MJ: Green tea polyphenol epigallocatechin 3-gallate, contributes to the degradation of DNMT3A and HDAC3 in HCT 116 human colon cancer cells. Anticancer Res 33, 5325–5333, 2013.
   PubMed Web of Science ®Google Scholar
• Medina-Franco JL, López-Vallejo F, Kuck D, and Lyko F: Natural products as DNA methyltransferase inhibitors: a computer-aided discovery approach. Mol Divers 15, 293–304, 2011.
   PubMed Web of Science ®Google Scholar
• Fang M, Chen D, and Yang CS: Dietary polyphenols may affect DNA methylation. J Nutr 137, 223S–228S, 2007.
   PubMed Web of Science ®Google Scholar
• Darvesh AS, Aggarwal BB, and Bishayee A: Curcumin and liver cancer: a review. Curr Pharm Biotechnol 13, 218–228, 2012.
   PubMed Web of Science ®Google Scholar
• Teiten MH, Dicato M, and Diederich M: Curcumin as a regulator of epigenetic events. Mol Nutr Food Res 57, 1619–1629, 2013.
   PubMed Web of Science ®Google Scholar
• Lee WJ and Zhu BT: Inhibition of DNA methylation by caffeic acid and chlorogenic acid, two common catechol-containing coffee polyphenols. Carcinogenesis 27, 269–277, 2006.
   PubMed Web of Science ®Google Scholar
• Furtado KS, Polletini J, Dias MC, Rodrigues MA, and Barbisan LF: Prevention of rat liver fibrosis and carcinogenesis by coffee and caffeine. Food Chem Toxicol 64, 20–26, 2014.
   PubMed Web of Science ®Google Scholar
• Wang W, Xu L, Kong J, Fan H, and Yang P: Quantitative research of histone H3 acetylation levels of human hepatocellular carcinoma cells. Bioanalysis 5, 327–339, 2013.
   PubMed Web of Science ®Google Scholar
• Rikimaru T, Taketomi A, Yamashita Y, Shirabe K, Hamatsu T, et al.: Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. Oncology 72, 69–74, 2007.
   PubMed Web of Science ®Google Scholar
• Quint K, Agaimy A, Di Fazio P, Montalbano R, Steindorf C, et al.: Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. Virchows Arch 459, 129–139, 2011.
   PubMed Web of Science ®Google Scholar
• Feng GW, Dong LD, Shang WJ, Pang XL, Li JF, et al.: HDAC5 promotes cell proliferation in human hepatocellular carcinoma by up-regulating Six1 expression. Eur Rev Med Pharmacol Sci 18, 811–816, 2014.
   PubMed Web of Science ®Google Scholar
• Park BL, Kim YJ, Cheong HS, Lee SO, Han CS, et al.: HDAC10 promoter polymorphism associated with development of HCC among chronic HBV patients. Biochem Biophys Res Commun 363, 776–781, 2007.
   PubMed Web of Science ®Google Scholar
• Yang Z, Zhou L, Wu LM, Xie HY, Zhang F, et al.: Combination of polymorphisms within the HDAC1 and HDAC3 gene predict tumor recurrence in hepatocellular carcinoma patients that have undergone transplant therapy. Clin Chem Lab Med 48, 1785–1791, 2010.
   PubMed Web of Science ®Google Scholar
• Wang HG, Huang XD, Shen P, Li LR, Xue HT, et al.: Anticancer effects of sodium butyrate on hepatocellular carcinoma cells in vitro. Int J Mol Med 31, 967–974, 2013.
   PubMed Web of Science ®Google Scholar
• Kuroiwa-Trzmielina J, de Conti A, Scolastici C, Pereira D, Horst MA, et al.: Chemoprevention of rat hepatocarcinogenesis with histone deacetylase inhibitors: efficacy of tributyrin, a butyric acid prodrug. Int J Cancer 124, 2520–2527, 2009.
   PubMed Web of Science ®Google Scholar
• de Conti A, Tryndyak V, Koturbash I, Heidor R, Kuroiwa-Trzmielina J, et al.: The chemopreventive activity of the butyric acid prodrug tributyrin in experimental rat hepatocarcinogenesis is associated with p53 acetylation and activation of the p53 apoptotic signaling pathway. Carcinogenesis 34, 1900–1906, 2013.
   PubMed Web of Science ®Google Scholar
• Coradini D, Zorzet S, Rossin R, Scarlata I, Pellizzro C, et al.: Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But. Clin Cancer Res 10, 4822–4830, 2004.
   PubMed Web of Science ®Google Scholar
• Coradini D and Speranza A: Histone deacetylase inhibitors for treatment of hepatocellular carcinoma. Acta Pharmacol Sin 26, 1025–1033, 2005.
   PubMed Web of Science ®Google Scholar
• Bishayee A and Dhir N: Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis. Chem Biol Interact 179, 131–144, 2009.
   PubMed Web of Science ®Google Scholar
• Bishayee A, Politis T, and Darvesh AS: Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma. Cancer Treat Rev 36, 43–53, 2010.
   PubMed Web of Science ®Google Scholar
• Bishayee A, Waghray A, Barnes KF, Mbimba T, Bhatia D, et al.: Suppression of the inflammatory cascade is implicated in resveratrol chemoprevention of experimental hepatocarcinogenesis. Pharm Res 27, 1080–1091, 2010.
   PubMed Web of Science ®Google Scholar
• Venturelli S, Berger A, Böcker A, Busch C, Weiland T, et al.: Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone [corrected] proteins in human-derived hepatoblastoma cells. PLoS One 8, e73097, 2013.
   PubMed Web of Science ®Google Scholar
• Knutson MD and Leeuwenburgh C: Resveratrol and novel potent activators of SIRT1: effects on aging and age-related diseases. Nutr Rev 66, 591–596, 2008.
   PubMed Web of Science ®Google Scholar
• Binda O, Nassif C, and Branton PE: SIRT1 negatively regulates HDAC1-dependent transcriptional repression by the RBP1 family of proteins. Oncogene 27, 3384–3392, 2008.
   PubMed Web of Science ®Google Scholar
• Scuto A, Kirschbaum M, Buettner R, Kujawski M, Cermak JM, et al.: SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-κB/STAT3 complex to its promoter in malignant lymphoid cells. Cell Death Dis 4, e635, 2013.
   PubMed Web of Science ®Google Scholar
• Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, et al.: Mammalian SIRT1 represses forkhead transcription factors. Cell 116, 551–563, 2004.
   PubMed Web of Science ®Google Scholar
• van der Horst A, Tertoolen LG, de Vries-Smits LM, Frye RA, Medema RH, et al.: FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir2(SIRT1). J Biol Chem 279, 28873–28879, 2004.
   PubMed Web of Science ®Google Scholar
• Yun JM, Chien A, Jialal I, and Devaraj S: Resveratrol up-regulates SIRT1 and inhibits cellular oxidative stress in the diabetic milieu: mechanistic insights. J Nutr Biochem 23, 699–705, 2012.
   PubMed Web of Science ®Google Scholar
• Halliwell B: Antioxidant defence mechanisms: from the beginning to the end (of the beginning). Free Radic Res 21, 261–272, 1999.
   Web of Science ®Google Scholar
• Lee H, Zhang P, Herrmann A, Yang C, Xin H, et al.: Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. Proc Natl Acad Sci USA 109, 7765–7769, 2012.
   PubMed Web of Science ®Google Scholar
• Stefanska B, Salamé P, Bednarek A, and Fabianowska-Majewska K: Comparative effects of retinoic acid, vitamin D and resveratrol and in combination with adenosine analogues on methylation and expression of phosphatase and tensin tumour suppressor gene in breast cancer cells. Br J Nutr 107, 781–790, 2012.
   PubMed Web of Science ®Google Scholar
• Papoutsis AJ, Borg JL, Selmin OI, and Romagnolo DF: BRCA-1 promoter hypermethylation and silencing induced by the aromatic hydrocarbon receptor-ligand TCDD are prevented by resveratrol in MCF-7 cells. J Nutr Biochem 23, 1324–1332, 2012.
   PubMed Web of Science ®Google Scholar
• Kala R, Shah HN, Martin SL, and Tollefsbol TO: Epigenetic-based combinatorial resveratrol and pterostilbene alters DNA damage response by affecting SIRT1 and DNMT enzyme expression, including SIRT1-dependent γ-H2AX and telomerase regulation in triple-negative breast cancer. BMC Cancer 15, 672, 2015.
   PubMed Web of Science ®Google Scholar
• Clarke JD, Dashwood RH, and Ho E: Multi-targeted prevention of cancer by sulforaphane. Cancer Lett 269, 291–304, 2008.
   PubMed Web of Science ®Google Scholar
• Yoxall V, Kentish P, Coldham N, Kuhnert N, Sauer MJ, et al.: Modulation of hepatic cytochromes P450 and phase II enzymes by dietary doses of sulforaphane in rats: implications for its chemopreventive activity. Int J Cancer 117, 356–362, 2005.
   PubMed Web of Science ®Google Scholar
• Hu R, Xu C, Shen G, Jain MR, Khor TO, et al.: Gene expression profiles induced by cancer chemopreventive isothiocyanate sulforaphane in the liver of C57BL/6J mice and C57BL/6J/Nrf2 (−/−) mice. Cancer Lett 243, 170–192, 2006.
   PubMed Web of Science ®Google Scholar
• Yates MS and Kensler TW: Keap1 eye on the target: chemoprevention of liver cancer. Acta Pharmacol Sin 28, 1331–1342, 2007.
   PubMed Web of Science ®Google Scholar
• Techapiesancharoenkij N, Fiala JL, Navasumrit P, Croy RG, Wogan GN, et al.: Sulforaphane, a cancer chemopreventive agent, induces pathways associated with membrane biosynthesis in response to tissue damage by aflatoxin B1. Toxicol Appl Pharmacol 282, 52–60, 2015.
   PubMed Web of Science ®Google Scholar
• Landis-Piwowar KR and Iyer NR: Cancer chemoprevention: current state of the art. Cancer Growth Metastasis 7, 19–25, 2014.
   PubMedGoogle Scholar
• Hong F, Freeman ML, and Liebler DC: Identification of sensor cysteines in human Keap1 modified by the cancer chemopreventive agent sulforaphane. Chem Res Toxicol 18, 1917–1926, 2005.
   PubMed Web of Science ®Google Scholar
• Myzak MC, Karplus PA, Chung FL, and Dashwood RH: A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res 64, 5767–5774, 2004.
   PubMed Web of Science ®Google Scholar
• Ho E, Clarke JD, and Dashwood RH: Dietary sulforaphane, a histone deacetylase inhibitor for cancer prevention. J Nutr 139, 2393–2396, 2009.
   PubMed Web of Science ®Google Scholar
• Gao Y and Tollefsbol TO: Impact of epigenetic dietary components on cancer through histone modifications. Curr Med Chem 22, 2051–2064, 2015.
   PubMed Web of Science ®Google Scholar
• Tortorella SM, Royce SG, Licciardi PV, and Karagiannis TC: Dietary sulforaphane in cancer chemoprevention: the role of epigenetic regulation and HDAC inhibition. Antioxid Redox Signal 22, 1382–1424, 2015.
   PubMed Web of Science ®Google Scholar
• Thakur VS, Gupta K, and Gupta S: Green tea polyphenols increase p53 transcriptional activity and acetylation by suppressing class I histone deacetylases. Int J Oncol 41, 353–361, 2012.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Krauthauser C, Maduskuie V, Fawcett PT, Olson JM, et al.: Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo. BMC Cancer 11, 144, 2011.
   PubMed Web of Science ®Google Scholar
• Lea MA, Randolph VM, Lee JE, and desBordes C: Induction of histone acetylation in mouse erythroleukemia cells by some organosulfur compounds including allyl isothiocyanate. Int J Cancer 92, 784–789, 2001.
   PubMed Web of Science ®Google Scholar
• Marquardt JU, Gomez-Quiroz L, Arreguin Camacho LO, Pinna F, Lee YH, et al.: Curcumin effectively inhibits oncogenic NF-kB signaling and restrains stemness features in liver cancer. J Hepatol 63, 661–669, 2015.
   PubMed Web of Science ®Google Scholar
• Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, et al.: Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137, 1005–1017, 2009.
   PubMed Web of Science ®Google Scholar
• Hsu SH, Wang B, Kota J, Yu J, Costinean S, et al.: Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest 122, 2871–2883, 2012.
   PubMed Web of Science ®Google Scholar
• Palmer JD, Soule BP, Simone BA, Zaorsky NG, Jin L, et al.: MicroRNA expression altered by diet: can food be medicinal? Ageing Res Rev 17, 16–24, 2014.
   PubMed Web of Science ®Google Scholar
• Ross SA and Davis CD: The emerging role of microRNAs and nutrition in modulating health and disease. Annu Rev Nutr 34, 305–336, 2014.
   PubMed Web of Science ®Google Scholar
• Tsang WP and Kwok TT: Epigallocatechin gallate up-regulation of miR-16 and induction of apoptosis in human cancer cells. J Nutr Biochem 21, 140–146, 2010.
   PubMed Web of Science ®Google Scholar
• Wagner AE, Boesch-Saadatmandi C, Dose J, Schultheiss G, and Rimbach G: Anti-inflammatory potential of allyl-isothiocyanate—role of Nrf2, NF-(κ) B and microRNA-155. J Cell Mol Med 16, 836–843, 2012.
   PubMed Web of Science ®Google Scholar
• Zhang Y: Allyl isothiocyanate as a cancer chemopreventive phytochemical. Mol Nutr Food Res 54, 127–135, 2010.
   PubMed Web of Science ®Google Scholar
• Umar A, Dunn BK, and Greenwald P: Future directions in cancer prevention. Nat Rev Cancer 12, 835–848, 2012.
   PubMed Web of Science ®Google Scholar
• Church RJ, Gatti DM, Urban TJ, Long N, Yang X, et al.: Sensitivity to hepatotoxicity due to epigallotechin gallate is affected by genetic background in diversity outbred mice. Food Chem Toxicol 76, 19–26, 2015.
   PubMed Web of Science ®Google Scholar
• Steward WP and Brown K: Cancer chemoprevention: a rapidly evolving field. Br J Cancer 109, 1–7, 2013.
   PubMed Web of Science ®Google Scholar
• Guariento AH, Furtado KS, de Conti A, Campos A, Purgatto E, et al.: Transcriptomic responses provide a new mechanistic basis for the chemopreventive effects of folic acid and tributyrin in rat liver carcinogenesis. Int J Cancer 135, 7–18, 2014.
   PubMed Web of Science ®Google Scholar